nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—ABCB1—Lisinopril—dilated cardiomyopathy	0.122	0.532	CbGbCtD
Nefazodone—ABCB1—Spironolactone—dilated cardiomyopathy	0.107	0.468	CbGbCtD
Nefazodone—Breast pain—Spironolactone—dilated cardiomyopathy	0.0115	0.0203	CcSEcCtD
Nefazodone—Trifluoperazine—TNNC1—dilated cardiomyopathy	0.0108	0.783	CrCbGaD
Nefazodone—Gynaecomastia—Spironolactone—dilated cardiomyopathy	0.00895	0.0158	CcSEcCtD
Nefazodone—Bursitis—Lisinopril—dilated cardiomyopathy	0.00845	0.0149	CcSEcCtD
Nefazodone—Apathy—Furosemide—dilated cardiomyopathy	0.00762	0.0135	CcSEcCtD
Nefazodone—Flat affect—Furosemide—dilated cardiomyopathy	0.00755	0.0133	CcSEcCtD
Nefazodone—Ataxia—Spironolactone—dilated cardiomyopathy	0.00683	0.0121	CcSEcCtD
Nefazodone—Nephrolithiasis—Furosemide—dilated cardiomyopathy	0.00677	0.012	CcSEcCtD
Nefazodone—Pelvic pain—Lisinopril—dilated cardiomyopathy	0.00671	0.0119	CcSEcCtD
Nefazodone—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.00654	0.0116	CcSEcCtD
Nefazodone—Gastritis—Spironolactone—dilated cardiomyopathy	0.00643	0.0114	CcSEcCtD
Nefazodone—Gout—Furosemide—dilated cardiomyopathy	0.00583	0.0103	CcSEcCtD
Nefazodone—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00578	0.0102	CcSEcCtD
Nefazodone—Laryngitis—Lisinopril—dilated cardiomyopathy	0.00567	0.01	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00555	0.0098	CcSEcCtD
Nefazodone—Memory impairment—Lisinopril—dilated cardiomyopathy	0.0052	0.00919	CcSEcCtD
Nefazodone—Urine output increased—Furosemide—dilated cardiomyopathy	0.00492	0.00869	CcSEcCtD
Nefazodone—Bladder pain—Furosemide—dilated cardiomyopathy	0.00492	0.00869	CcSEcCtD
Nefazodone—Lightheadedness—Furosemide—dilated cardiomyopathy	0.00487	0.0086	CcSEcCtD
Nefazodone—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00475	0.00839	CcSEcCtD
Nefazodone—Mental disability—Furosemide—dilated cardiomyopathy	0.00472	0.00834	CcSEcCtD
Nefazodone—Breast pain—Lisinopril—dilated cardiomyopathy	0.00468	0.00827	CcSEcCtD
Nefazodone—Accidental injury—Lisinopril—dilated cardiomyopathy	0.00462	0.00815	CcSEcCtD
Nefazodone—Ventricular extrasystoles—Lisinopril—dilated cardiomyopathy	0.00452	0.00799	CcSEcCtD
Nefazodone—Polyuria—Furosemide—dilated cardiomyopathy	0.0045	0.00795	CcSEcCtD
Nefazodone—Cough increased—Lisinopril—dilated cardiomyopathy	0.00446	0.00788	CcSEcCtD
Nefazodone—Alopecia—Spironolactone—dilated cardiomyopathy	0.00444	0.00784	CcSEcCtD
Nefazodone—Oliguria—Lisinopril—dilated cardiomyopathy	0.00443	0.00783	CcSEcCtD
Nefazodone—Deafness—Furosemide—dilated cardiomyopathy	0.00442	0.0078	CcSEcCtD
Nefazodone—Gout—Lisinopril—dilated cardiomyopathy	0.00437	0.00773	CcSEcCtD
Nefazodone—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.0042	0.00743	CcSEcCtD
Nefazodone—Thirst—Furosemide—dilated cardiomyopathy	0.00415	0.00733	CcSEcCtD
Nefazodone—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00413	0.0073	CcSEcCtD
Nefazodone—Neck pain—Lisinopril—dilated cardiomyopathy	0.00413	0.0073	CcSEcCtD
Nefazodone—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00406	0.00717	CcSEcCtD
Nefazodone—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00399	0.00705	CcSEcCtD
Nefazodone—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00397	0.00701	CcSEcCtD
Nefazodone—Salivary hypersecretion—Lisinopril—dilated cardiomyopathy	0.00397	0.00701	CcSEcCtD
Nefazodone—Malaise—Spironolactone—dilated cardiomyopathy	0.00394	0.00697	CcSEcCtD
Nefazodone—Cystitis—Lisinopril—dilated cardiomyopathy	0.00394	0.00697	CcSEcCtD
Nefazodone—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00391	0.00691	CcSEcCtD
Nefazodone—Photophobia—Lisinopril—dilated cardiomyopathy	0.00383	0.00677	CcSEcCtD
Nefazodone—Urinary retention—Furosemide—dilated cardiomyopathy	0.00376	0.00664	CcSEcCtD
Nefazodone—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00369	0.00652	CcSEcCtD
Nefazodone—Discomfort—Spironolactone—dilated cardiomyopathy	0.00368	0.0065	CcSEcCtD
Nefazodone—Dehydration—Furosemide—dilated cardiomyopathy	0.00367	0.00649	CcSEcCtD
Nefazodone—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.00365	0.00645	CcSEcCtD
Nefazodone—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00361	0.00637	CcSEcCtD
Nefazodone—Confusional state—Spironolactone—dilated cardiomyopathy	0.0036	0.00636	CcSEcCtD
Nefazodone—Hypertonia—Lisinopril—dilated cardiomyopathy	0.00358	0.00632	CcSEcCtD
Nefazodone—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00357	0.0063	CcSEcCtD
Nefazodone—Cramp muscle—Furosemide—dilated cardiomyopathy	0.00356	0.00628	CcSEcCtD
Nefazodone—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00349	0.00617	CcSEcCtD
Nefazodone—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00344	0.00607	CcSEcCtD
Nefazodone—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00334	0.00591	CcSEcCtD
Nefazodone—Eczema—Lisinopril—dilated cardiomyopathy	0.0033	0.00583	CcSEcCtD
Nefazodone—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.0033	0.00583	CcSEcCtD
Nefazodone—Injury—Lisinopril—dilated cardiomyopathy	0.00323	0.0057	CcSEcCtD
Nefazodone—Libido decreased—Lisinopril—dilated cardiomyopathy	0.0032	0.00565	CcSEcCtD
Nefazodone—Somnolence—Spironolactone—dilated cardiomyopathy	0.00317	0.0056	CcSEcCtD
Nefazodone—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00315	0.00557	CcSEcCtD
Nefazodone—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00312	0.00551	CcSEcCtD
Nefazodone—Arthritis—Lisinopril—dilated cardiomyopathy	0.00305	0.00539	CcSEcCtD
Nefazodone—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00304	0.00537	CcSEcCtD
Nefazodone—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00303	0.00534	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00302	0.00533	CcSEcCtD
Nefazodone—Aripiprazole—ADRB1—dilated cardiomyopathy	0.003	0.217	CrCbGaD
Nefazodone—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00298	0.00526	CcSEcCtD
Nefazodone—Diplopia—Lisinopril—dilated cardiomyopathy	0.00296	0.00524	CcSEcCtD
Nefazodone—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00296	0.00524	CcSEcCtD
Nefazodone—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00294	0.0052	CcSEcCtD
Nefazodone—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00294	0.00519	CcSEcCtD
Nefazodone—Sweating—Furosemide—dilated cardiomyopathy	0.00292	0.00516	CcSEcCtD
Nefazodone—Face oedema—Lisinopril—dilated cardiomyopathy	0.00286	0.00506	CcSEcCtD
Nefazodone—Urticaria—Spironolactone—dilated cardiomyopathy	0.00284	0.00501	CcSEcCtD
Nefazodone—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00282	0.00498	CcSEcCtD
Nefazodone—Ataxia—Lisinopril—dilated cardiomyopathy	0.00279	0.00492	CcSEcCtD
Nefazodone—Dehydration—Lisinopril—dilated cardiomyopathy	0.00276	0.00487	CcSEcCtD
Nefazodone—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00271	0.00478	CcSEcCtD
Nefazodone—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.00267	0.00472	CcSEcCtD
Nefazodone—Visual impairment—Furosemide—dilated cardiomyopathy	0.00263	0.00465	CcSEcCtD
Nefazodone—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00263	0.00464	CcSEcCtD
Nefazodone—Gastritis—Lisinopril—dilated cardiomyopathy	0.00262	0.00463	CcSEcCtD
Nefazodone—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00258	0.00456	CcSEcCtD
Nefazodone—Asthma—Lisinopril—dilated cardiomyopathy	0.00256	0.00453	CcSEcCtD
Nefazodone—Influenza—Lisinopril—dilated cardiomyopathy	0.00256	0.00453	CcSEcCtD
Nefazodone—Tinnitus—Furosemide—dilated cardiomyopathy	0.00255	0.0045	CcSEcCtD
Nefazodone—Pruritus—Spironolactone—dilated cardiomyopathy	0.00253	0.00446	CcSEcCtD
Nefazodone—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.0025	0.00441	CcSEcCtD
Nefazodone—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00246	0.00435	CcSEcCtD
Nefazodone—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00244	0.00431	CcSEcCtD
Nefazodone—Dysuria—Lisinopril—dilated cardiomyopathy	0.0024	0.00423	CcSEcCtD
Nefazodone—Dizziness—Spironolactone—dilated cardiomyopathy	0.00236	0.00417	CcSEcCtD
Nefazodone—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00236	0.00417	CcSEcCtD
Nefazodone—Flatulence—Furosemide—dilated cardiomyopathy	0.00234	0.00414	CcSEcCtD
Nefazodone—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00234	0.00413	CcSEcCtD
Nefazodone—Weight increased—Lisinopril—dilated cardiomyopathy	0.00233	0.00412	CcSEcCtD
Nefazodone—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00233	0.00412	CcSEcCtD
Nefazodone—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00232	0.00409	CcSEcCtD
Nefazodone—Pneumonia—Lisinopril—dilated cardiomyopathy	0.0023	0.00406	CcSEcCtD
Nefazodone—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00229	0.00404	CcSEcCtD
Nefazodone—Vomiting—Spironolactone—dilated cardiomyopathy	0.00227	0.00401	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00226	0.004	CcSEcCtD
Nefazodone—Rash—Spironolactone—dilated cardiomyopathy	0.00225	0.00398	CcSEcCtD
Nefazodone—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00225	0.00397	CcSEcCtD
Nefazodone—Vision blurred—Furosemide—dilated cardiomyopathy	0.00224	0.00396	CcSEcCtD
Nefazodone—Headache—Spironolactone—dilated cardiomyopathy	0.00224	0.00395	CcSEcCtD
Nefazodone—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00222	0.00392	CcSEcCtD
Nefazodone—Anaemia—Furosemide—dilated cardiomyopathy	0.0022	0.00388	CcSEcCtD
Nefazodone—Sweating—Lisinopril—dilated cardiomyopathy	0.00219	0.00387	CcSEcCtD
Nefazodone—Agitation—Furosemide—dilated cardiomyopathy	0.00219	0.00386	CcSEcCtD
Nefazodone—Haematuria—Lisinopril—dilated cardiomyopathy	0.00218	0.00385	CcSEcCtD
Nefazodone—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00215	0.00381	CcSEcCtD
Nefazodone—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00214	0.00379	CcSEcCtD
Nefazodone—Vertigo—Furosemide—dilated cardiomyopathy	0.00214	0.00378	CcSEcCtD
Nefazodone—Leukopenia—Furosemide—dilated cardiomyopathy	0.00213	0.00376	CcSEcCtD
Nefazodone—Nausea—Spironolactone—dilated cardiomyopathy	0.00212	0.00374	CcSEcCtD
Nefazodone—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00209	0.00369	CcSEcCtD
Nefazodone—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00206	0.00363	CcSEcCtD
Nefazodone—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00205	0.00362	CcSEcCtD
Nefazodone—Hallucination—Lisinopril—dilated cardiomyopathy	0.00204	0.0036	CcSEcCtD
Nefazodone—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00204	0.0036	CcSEcCtD
Nefazodone—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00202	0.00357	CcSEcCtD
Nefazodone—Dry mouth—Furosemide—dilated cardiomyopathy	0.00198	0.0035	CcSEcCtD
Nefazodone—Confusional state—Furosemide—dilated cardiomyopathy	0.00196	0.00346	CcSEcCtD
Nefazodone—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00194	0.00343	CcSEcCtD
Nefazodone—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00194	0.00342	CcSEcCtD
Nefazodone—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00191	0.00338	CcSEcCtD
Nefazodone—Shock—Furosemide—dilated cardiomyopathy	0.00191	0.00337	CcSEcCtD
Nefazodone—Flushing—Lisinopril—dilated cardiomyopathy	0.0019	0.00336	CcSEcCtD
Nefazodone—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.0019	0.00336	CcSEcCtD
Nefazodone—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00188	0.00332	CcSEcCtD
Nefazodone—Anorexia—Furosemide—dilated cardiomyopathy	0.00185	0.00327	CcSEcCtD
Nefazodone—Chills—Lisinopril—dilated cardiomyopathy	0.00184	0.00325	CcSEcCtD
Nefazodone—Hypotension—Furosemide—dilated cardiomyopathy	0.00181	0.00321	CcSEcCtD
Nefazodone—Alopecia—Lisinopril—dilated cardiomyopathy	0.00181	0.0032	CcSEcCtD
Nefazodone—Flatulence—Lisinopril—dilated cardiomyopathy	0.00176	0.00311	CcSEcCtD
Nefazodone—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00175	0.00309	CcSEcCtD
Nefazodone—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00174	0.00308	CcSEcCtD
Nefazodone—Back pain—Lisinopril—dilated cardiomyopathy	0.00173	0.00305	CcSEcCtD
Nefazodone—Somnolence—Furosemide—dilated cardiomyopathy	0.00173	0.00305	CcSEcCtD
Nefazodone—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00172	0.00303	CcSEcCtD
Nefazodone—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00169	0.00298	CcSEcCtD
Nefazodone—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00168	0.00297	CcSEcCtD
Nefazodone—Tremor—Lisinopril—dilated cardiomyopathy	0.00167	0.00295	CcSEcCtD
Nefazodone—Pain—Furosemide—dilated cardiomyopathy	0.00166	0.00293	CcSEcCtD
Nefazodone—Constipation—Furosemide—dilated cardiomyopathy	0.00166	0.00293	CcSEcCtD
Nefazodone—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00166	0.00293	CcSEcCtD
Nefazodone—Anaemia—Lisinopril—dilated cardiomyopathy	0.00165	0.00291	CcSEcCtD
Nefazodone—Angioedema—Lisinopril—dilated cardiomyopathy	0.00163	0.00288	CcSEcCtD
Nefazodone—Malaise—Lisinopril—dilated cardiomyopathy	0.00161	0.00284	CcSEcCtD
Nefazodone—Vertigo—Lisinopril—dilated cardiomyopathy	0.0016	0.00283	CcSEcCtD
Nefazodone—Syncope—Lisinopril—dilated cardiomyopathy	0.0016	0.00283	CcSEcCtD
Nefazodone—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.0016	0.00283	CcSEcCtD
Nefazodone—Leukopenia—Lisinopril—dilated cardiomyopathy	0.0016	0.00282	CcSEcCtD
Nefazodone—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00159	0.0028	CcSEcCtD
Nefazodone—Palpitations—Lisinopril—dilated cardiomyopathy	0.00158	0.00279	CcSEcCtD
Nefazodone—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00157	0.00277	CcSEcCtD
Nefazodone—Cough—Lisinopril—dilated cardiomyopathy	0.00156	0.00275	CcSEcCtD
Nefazodone—Urticaria—Furosemide—dilated cardiomyopathy	0.00154	0.00272	CcSEcCtD
Nefazodone—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00154	0.00271	CcSEcCtD
Nefazodone—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00154	0.00271	CcSEcCtD
Nefazodone—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00152	0.00268	CcSEcCtD
Nefazodone—Myalgia—Lisinopril—dilated cardiomyopathy	0.00152	0.00268	CcSEcCtD
Nefazodone—Chest pain—Lisinopril—dilated cardiomyopathy	0.00152	0.00268	CcSEcCtD
Nefazodone—Anxiety—Lisinopril—dilated cardiomyopathy	0.00151	0.00268	CcSEcCtD
Nefazodone—Discomfort—Lisinopril—dilated cardiomyopathy	0.0015	0.00265	CcSEcCtD
Nefazodone—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00149	0.00263	CcSEcCtD
Nefazodone—Confusional state—Lisinopril—dilated cardiomyopathy	0.00147	0.00259	CcSEcCtD
Nefazodone—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00146	0.00257	CcSEcCtD
Nefazodone—Oedema—Lisinopril—dilated cardiomyopathy	0.00146	0.00257	CcSEcCtD
Nefazodone—Infection—Lisinopril—dilated cardiomyopathy	0.00145	0.00256	CcSEcCtD
Nefazodone—Shock—Lisinopril—dilated cardiomyopathy	0.00143	0.00253	CcSEcCtD
Nefazodone—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00143	0.00253	CcSEcCtD
Nefazodone—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00143	0.00252	CcSEcCtD
Nefazodone—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00142	0.00251	CcSEcCtD
Nefazodone—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00141	0.00249	CcSEcCtD
Nefazodone—Asthenia—Furosemide—dilated cardiomyopathy	0.00139	0.00246	CcSEcCtD
Nefazodone—Anorexia—Lisinopril—dilated cardiomyopathy	0.00139	0.00245	CcSEcCtD
Nefazodone—Pruritus—Furosemide—dilated cardiomyopathy	0.00137	0.00243	CcSEcCtD
Nefazodone—Hypotension—Lisinopril—dilated cardiomyopathy	0.00136	0.0024	CcSEcCtD
Nefazodone—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00133	0.00235	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00133	0.00234	CcSEcCtD
Nefazodone—Insomnia—Lisinopril—dilated cardiomyopathy	0.00132	0.00233	CcSEcCtD
Nefazodone—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00131	0.00231	CcSEcCtD
Nefazodone—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.0013	0.00229	CcSEcCtD
Nefazodone—Somnolence—Lisinopril—dilated cardiomyopathy	0.0013	0.00229	CcSEcCtD
Nefazodone—Dizziness—Furosemide—dilated cardiomyopathy	0.00128	0.00227	CcSEcCtD
Nefazodone—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00128	0.00227	CcSEcCtD
Nefazodone—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00127	0.00224	CcSEcCtD
Nefazodone—Constipation—Lisinopril—dilated cardiomyopathy	0.00125	0.0022	CcSEcCtD
Nefazodone—Pain—Lisinopril—dilated cardiomyopathy	0.00125	0.0022	CcSEcCtD
Nefazodone—Vomiting—Furosemide—dilated cardiomyopathy	0.00123	0.00218	CcSEcCtD
Nefazodone—Rash—Furosemide—dilated cardiomyopathy	0.00122	0.00216	CcSEcCtD
Nefazodone—Dermatitis—Furosemide—dilated cardiomyopathy	0.00122	0.00216	CcSEcCtD
Nefazodone—Headache—Furosemide—dilated cardiomyopathy	0.00122	0.00215	CcSEcCtD
Nefazodone—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.0012	0.00212	CcSEcCtD
Nefazodone—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00119	0.0021	CcSEcCtD
Nefazodone—Urticaria—Lisinopril—dilated cardiomyopathy	0.00116	0.00204	CcSEcCtD
Nefazodone—Nausea—Furosemide—dilated cardiomyopathy	0.00115	0.00204	CcSEcCtD
Nefazodone—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00115	0.00203	CcSEcCtD
Nefazodone—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00115	0.00203	CcSEcCtD
Nefazodone—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00107	0.0019	CcSEcCtD
Nefazodone—Asthenia—Lisinopril—dilated cardiomyopathy	0.00105	0.00185	CcSEcCtD
Nefazodone—Pruritus—Lisinopril—dilated cardiomyopathy	0.00103	0.00182	CcSEcCtD
Nefazodone—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000997	0.00176	CcSEcCtD
Nefazodone—Dizziness—Lisinopril—dilated cardiomyopathy	0.000963	0.0017	CcSEcCtD
Nefazodone—Vomiting—Lisinopril—dilated cardiomyopathy	0.000926	0.00164	CcSEcCtD
Nefazodone—Rash—Lisinopril—dilated cardiomyopathy	0.000919	0.00162	CcSEcCtD
Nefazodone—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000918	0.00162	CcSEcCtD
Nefazodone—Headache—Lisinopril—dilated cardiomyopathy	0.000913	0.00161	CcSEcCtD
Nefazodone—Nausea—Lisinopril—dilated cardiomyopathy	0.000865	0.00153	CcSEcCtD
Nefazodone—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000186	0.000974	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—TAZ—dilated cardiomyopathy	0.000184	0.000964	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000182	0.000956	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—SDHA—dilated cardiomyopathy	0.000181	0.000951	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000178	0.000933	CbGpPWpGaD
Nefazodone—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000178	0.000932	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000177	0.000926	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000173	0.000907	CbGpPWpGaD
Nefazodone—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000172	0.000902	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000171	0.000899	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000169	0.000888	CbGpPWpGaD
Nefazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000168	0.000883	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000168	0.000882	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—SDHA—dilated cardiomyopathy	0.000166	0.000872	CbGpPWpGaD
Nefazodone—SLC6A3—Neuronal System—RAF1—dilated cardiomyopathy	0.000166	0.000869	CbGpPWpGaD
Nefazodone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000161	0.000846	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000161	0.000843	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000158	0.00083	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000158	0.00083	CbGpPWpGaD
Nefazodone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000158	0.000828	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000158	0.000826	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000158	0.000826	CbGpPWpGaD
Nefazodone—HTR1A—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000158	0.000826	CbGpPWpGaD
Nefazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000156	0.000821	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000152	0.000795	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000151	0.000791	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000151	0.000791	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000151	0.000791	CbGpPWpGaD
Nefazodone—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	0.000148	0.000774	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000147	0.000774	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000147	0.000772	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000146	0.000768	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000144	0.000757	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000144	0.000754	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000144	0.000754	CbGpPWpGaD
Nefazodone—ADRA2A—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	0.000143	0.000752	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000143	0.00075	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000143	0.00075	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000143	0.000748	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000142	0.000744	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.00014	0.000735	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	0.000139	0.000729	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—ITGB1—dilated cardiomyopathy	0.000139	0.000728	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	0.000139	0.000727	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000137	0.000718	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000137	0.000718	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000137	0.000717	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000137	0.000717	CbGpPWpGaD
Nefazodone—HTR2A—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000136	0.000714	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000136	0.000712	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000134	0.000703	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000134	0.000703	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000134	0.000701	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000133	0.000698	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000131	0.000687	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	0.000131	0.000685	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000129	0.000679	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000129	0.000676	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000128	0.000673	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000127	0.000668	CbGpPWpGaD
Nefazodone—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000127	0.000668	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000127	0.000667	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	0.000125	0.000658	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000125	0.000653	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000124	0.000653	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000124	0.000653	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000124	0.000652	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000124	0.000652	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000123	0.000647	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000123	0.000646	CbGpPWpGaD
Nefazodone—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000122	0.000639	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000122	0.000639	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000122	0.000638	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000122	0.000638	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000121	0.000635	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000121	0.000633	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000119	0.000625	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—CD36—dilated cardiomyopathy	0.000118	0.000621	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	0.000118	0.00062	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000116	0.000608	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000116	0.000607	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000116	0.000606	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000115	0.000606	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000115	0.000603	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000113	0.000593	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000113	0.000593	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000113	0.000593	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000112	0.000588	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000112	0.000587	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—RAC1—dilated cardiomyopathy	0.000112	0.000585	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000111	0.000585	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000111	0.00058	CbGpPWpGaD
Nefazodone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000111	0.00058	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.00011	0.000577	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.00011	0.000577	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.00011	0.000574	CbGpPWpGaD
Nefazodone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000108	0.000568	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000105	0.000552	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000105	0.000552	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000105	0.000551	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000105	0.00055	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000104	0.000547	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000103	0.00054	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000102	0.000534	CbGpPWpGaD
Nefazodone—SLC6A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000101	0.000527	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—ADRB2—dilated cardiomyopathy	9.99e-05	0.000524	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	9.98e-05	0.000523	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	9.77e-05	0.000512	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	9.57e-05	0.000502	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.57e-05	0.000502	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	9.55e-05	0.000501	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.52e-05	0.000499	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	9.35e-05	0.000491	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.11e-05	0.000478	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	9.09e-05	0.000477	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	9.08e-05	0.000476	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	9.06e-05	0.000475	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	8.97e-05	0.00047	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—RAC1—dilated cardiomyopathy	8.92e-05	0.000468	CbGpPWpGaD
Nefazodone—SLC6A3—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	8.9e-05	0.000467	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	8.87e-05	0.000465	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	8.69e-05	0.000456	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.57e-05	0.000449	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	8.54e-05	0.000448	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—RAC1—dilated cardiomyopathy	8.54e-05	0.000448	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.52e-05	0.000447	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.49e-05	0.000446	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.49e-05	0.000446	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.45e-05	0.000443	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.45e-05	0.000443	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PSEN2—dilated cardiomyopathy	8.26e-05	0.000433	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	8.24e-05	0.000432	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—AGT—dilated cardiomyopathy	8.16e-05	0.000428	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—RAC1—dilated cardiomyopathy	8.14e-05	0.000427	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—RAC1—dilated cardiomyopathy	8.1e-05	0.000425	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PSEN2—dilated cardiomyopathy	8.09e-05	0.000424	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.09e-05	0.000424	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.09e-05	0.000424	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.9e-05	0.000414	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.86e-05	0.000412	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—AGT—dilated cardiomyopathy	7.78e-05	0.000408	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—RAC1—dilated cardiomyopathy	7.75e-05	0.000407	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	7.75e-05	0.000406	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—AGT—dilated cardiomyopathy	7.74e-05	0.000406	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	7.73e-05	0.000405	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.65e-05	0.000401	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	7.64e-05	0.000401	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.61e-05	0.000399	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	7.59e-05	0.000398	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCR3—dilated cardiomyopathy	7.52e-05	0.000394	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PSEN2—dilated cardiomyopathy	7.52e-05	0.000394	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—AGT—dilated cardiomyopathy	7.41e-05	0.000389	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—AGT—dilated cardiomyopathy	7.4e-05	0.000388	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—RAF1—dilated cardiomyopathy	7.39e-05	0.000388	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCL2—dilated cardiomyopathy	7.34e-05	0.000385	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AGTR2—dilated cardiomyopathy	7.34e-05	0.000385	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.28e-05	0.000382	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	7.28e-05	0.000382	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—AGT—dilated cardiomyopathy	7.25e-05	0.00038	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	7.18e-05	0.000377	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	7.18e-05	0.000377	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	7.05e-05	0.00037	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—RAC1—dilated cardiomyopathy	7.03e-05	0.000369	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.89e-05	0.000361	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.82e-05	0.000358	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—AGT—dilated cardiomyopathy	6.73e-05	0.000353	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—AGT—dilated cardiomyopathy	6.72e-05	0.000353	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.68e-05	0.00035	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCL2—dilated cardiomyopathy	6.68e-05	0.00035	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AGTR2—dilated cardiomyopathy	6.68e-05	0.00035	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.61e-05	0.000347	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—AGT—dilated cardiomyopathy	6.58e-05	0.000345	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.53e-05	0.000343	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.5e-05	0.000341	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.47e-05	0.000339	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.4e-05	0.000336	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—GPX1—dilated cardiomyopathy	6.25e-05	0.000328	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.22e-05	0.000326	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.21e-05	0.000326	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.2e-05	0.000325	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.16e-05	0.000323	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—AGT—dilated cardiomyopathy	6.11e-05	0.000321	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—CD36—dilated cardiomyopathy	6.08e-05	0.000319	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	6.01e-05	0.000315	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.9e-05	0.00031	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.64e-05	0.000296	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.52e-05	0.00029	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—AGT—dilated cardiomyopathy	5.48e-05	0.000287	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.4e-05	0.000283	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.37e-05	0.000282	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.35e-05	0.000281	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.32e-05	0.000279	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.3e-05	0.000278	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.24e-05	0.000275	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.14e-05	0.00027	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.13e-05	0.000269	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.07e-05	0.000266	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GPX1—dilated cardiomyopathy	4.93e-05	0.000258	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.87e-05	0.000255	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—RAC1—dilated cardiomyopathy	4.81e-05	0.000252	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CD36—dilated cardiomyopathy	4.8e-05	0.000252	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—RAC1—dilated cardiomyopathy	4.79e-05	0.000251	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.66e-05	0.000245	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.6e-05	0.000241	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—AGT—dilated cardiomyopathy	4.6e-05	0.000241	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—RAC1—dilated cardiomyopathy	4.58e-05	0.00024	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AGT—dilated cardiomyopathy	4.57e-05	0.00024	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.57e-05	0.00024	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	4.51e-05	0.000237	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.5e-05	0.000236	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	4.43e-05	0.000232	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	4.4e-05	0.000231	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AGT—dilated cardiomyopathy	4.38e-05	0.00023	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—AGT—dilated cardiomyopathy	4.32e-05	0.000227	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.24e-05	0.000223	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.18e-05	0.000219	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RAC1—dilated cardiomyopathy	4.16e-05	0.000218	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RAC1—dilated cardiomyopathy	4.07e-05	0.000213	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AGT—dilated cardiomyopathy	3.97e-05	0.000208	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	3.96e-05	0.000208	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AGT—dilated cardiomyopathy	3.89e-05	0.000204	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RAC1—dilated cardiomyopathy	3.78e-05	0.000198	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.7e-05	0.000194	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.68e-05	0.000193	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AGT—dilated cardiomyopathy	3.61e-05	0.000189	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.53e-05	0.000185	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	3.41e-05	0.000179	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CD36—dilated cardiomyopathy	3.32e-05	0.000174	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	3.21e-05	0.000168	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.2e-05	0.000168	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—RAF1—dilated cardiomyopathy	3.19e-05	0.000167	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—RAF1—dilated cardiomyopathy	3.17e-05	0.000166	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	3.13e-05	0.000164	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	3.13e-05	0.000164	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—RAF1—dilated cardiomyopathy	3.04e-05	0.000159	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—AGT—dilated cardiomyopathy	2.99e-05	0.000157	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.91e-05	0.000153	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	2.81e-05	0.000148	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RAF1—dilated cardiomyopathy	2.76e-05	0.000145	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RAF1—dilated cardiomyopathy	2.7e-05	0.000142	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RAF1—dilated cardiomyopathy	2.51e-05	0.000131	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EGFR—dilated cardiomyopathy	2.19e-05	0.000115	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EGFR—dilated cardiomyopathy	2.18e-05	0.000114	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	2.1e-05	0.00011	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EGFR—dilated cardiomyopathy	2.08e-05	0.000109	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	2.04e-05	0.000107	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EGFR—dilated cardiomyopathy	1.89e-05	9.91e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EGFR—dilated cardiomyopathy	1.85e-05	9.7e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	1.84e-05	9.65e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EGFR—dilated cardiomyopathy	1.72e-05	9.02e-05	CbGpPWpGaD
